Pfizer Says FDA Is Still Reviewing Prevnar 13

NEW YORK (AP) ¿ Pfizer Inc. says the Food and Drug Administration is again extending its review of Prevnar 13, a children's pneumococcal vaccine.

The FDA's decision was due Wednesday, but Pfizer says the agency has not completed its review. It did not say when the process might be complete. The FDA was originally scheduled to make a decision by Sept. 30, but decided to extend that review by three months.

Prevnar 13 is intended to reduce the risk of infection by 13 types of pneumococcal disease, which can cause ear infections, meningitis, pneumonia and blood infections. It is a newer version of a vaccine that has been on the market for nine years, and considered one of the most important products Pfizer acquired when it bought rival Wyeth for $68 billion this year.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Food & Drink

Week of the Women From Finance to Fast Food

Week of the Women From Finance to Fast Food

The Demise of the Great American Supermarket (Watch!)

The Demise of the Great American Supermarket (Watch!)

The Great American Supermarket No Longer Reigns Supreme

The Great American Supermarket No Longer Reigns Supreme

Kohl's May Blame Winter Weather for First-Quarter Earnings Slip

Kohl's May Blame Winter Weather for First-Quarter Earnings Slip

Watch McDonald's Workers Storm HQ to Protest Fast-Food Giant's Pay

Watch McDonald's Workers Storm HQ to Protest Fast-Food Giant's Pay